About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status.